Table 2.
RIETE score items, according to cancer diagnosis 11 days–24 months after VTE
| No cancer diagnosis (n = 436) | Cancer diagnosis 11 days–24 months after VTE (n = 31) | OR (95% CI) | P value | |
|---|---|---|---|---|
| RIETE ≥ 3p, no. (%) | 114 (26) | 12 (39) | 1.78 (0.85–3.63) | 0.14 |
| Male sex (+ 1p), no. (%) | 244 (56) | 14 (45) | 0.65 (0.30–1.31) | 0.27 |
| Age over 70 (+ 2p), no. (%) | 182 (42) | 18 (58) | 1.93 (0.96–3.88) | 0.091 |
| COPD (+ 1p), no. (%) | 30 (6.9) | 7 (23) | 3.95 (1.53–9.38) | 0.0071 |
| Anemiaa (+ 2p), no. (%) | 86 (20) | 7 (23) | 1.19 (0.47–2.75) | 0.65 |
| Elevated plateletsb (+ 1p), no. (%) | 36 (8.3) | 1 (3.2) | 0.37 (0.035–2.07) | 0.50 |
| Recent surgery (− 2p), no. (%) | 49 (11) | 1 (3.2) | 0.26 (0.025–1.44) | 0.23 |
| Prior VTE (− 1p), no. (%) | 96 (22) | 8 (26) | 1.23 (0.57–2.73) | 0.66 |
CI Confidence interval, COPD chronic obstructive pulmonary disease, VTE venous thromboembolism
aAnemia was defined as hemoglobin < 130 g/l in men and < 120 g/l in women
bElevated platelets were defined as platelet count ≥ 350 × 109/l